David J Andorsky1, John M Timmerman. 1. University of California, Center for Health Sciences, Division of Hematology/Oncology, Department of Medicine, Los Angeles, CA 90095-1678, USA.
Abstract
BACKGROUND: IL-21, a recently described common gamma-chain cytokine, can induce the maturation and enhanced cytotoxicity of natural killer (NK) and CD8(+) T cells and proliferation of CD40-stimulated B cells. Exogenous IL-21 has antitumor effects in murine models via immunological mechanisms. In addition, IL-21 can also directly induce apoptosis in chronic lymphocytic leukemia cells and other B cell lymphomas. OBJECTIVE/ METHODS: We examine preclinical and clinical data regarding anticancer therapy with IL-21. Published original research, abstracts and ongoing clinical trials are reviewed. A brief summary of IL-21 biology is also provided. CONCLUSION: Three Phase I and II clinical trials with recombinant IL-21 have been completed, providing data on the safety and efficacy in subjects with advanced melanoma, renal cell carcinoma and non-Hodgkin's B cell lymphoma. Numerous additional single-agent and combination therapy clinical trials are ongoing for a variety of human malignancies. B cell malignancies in particular warrant further clinical investigation.
BACKGROUND:IL-21, a recently described common gamma-chain cytokine, can induce the maturation and enhanced cytotoxicity of natural killer (NK) and CD8(+) T cells and proliferation of CD40-stimulated B cells. Exogenous IL-21 has antitumor effects in murine models via immunological mechanisms. In addition, IL-21 can also directly induce apoptosis in chronic lymphocytic leukemia cells and other B cell lymphomas. OBJECTIVE/ METHODS: We examine preclinical and clinical data regarding anticancer therapy with IL-21. Published original research, abstracts and ongoing clinical trials are reviewed. A brief summary of IL-21 biology is also provided. CONCLUSION: Three Phase I and II clinical trials with recombinant IL-21 have been completed, providing data on the safety and efficacy in subjects with advanced melanoma, renal cell carcinoma and non-Hodgkin's B cell lymphoma. Numerous additional single-agent and combination therapy clinical trials are ongoing for a variety of humanmalignancies. B cell malignancies in particular warrant further clinical investigation.
Authors: Tao Wang; Alexis Cunningham; Ayotunde O Dokun; Surovi Hazarika; Kevin Houston; Lingdan Chen; R John Lye; Rosanne Spolski; Warren J Leonard; Brian H Annex Journal: Arterioscler Thromb Vasc Biol Date: 2015-04-02 Impact factor: 8.311
Authors: Daniela De Nitto; Massimiliano Sarra; Francesco Pallone; Giovanni Monteleone Journal: World J Gastroenterol Date: 2010-08-07 Impact factor: 5.742
Authors: John M Timmerman; John C Byrd; David J Andorsky; Reiko E Yamada; Janet Kramer; Natarajan Muthusamy; Naomi Hunder; John M Pagel Journal: Clin Cancer Res Date: 2012-08-14 Impact factor: 12.531
Authors: Magdalena Hagn; Sue E Blackwell; Thamara Beyer; Verena Ebel; Dorit Fabricius; Stefanie Lindner; Stefan Stilgenbauer; Thomas Simmet; Constantine Tam; Paul Neeson; Joseph A Trapani; Hubert Schrezenmeier; George J Weiner; Bernd Jahrsdörfer Journal: Int Immunol Date: 2014-02-04 Impact factor: 4.823
Authors: Cecile M Krejsa; Rick D Holly; Mark Heipel; Ken M Bannink; Rebecca Johnson; Richard Roque; Jane Heffernan; Julie Hill; Lay Chin; Felecia Wagener; Faith Shiota; Katherine Henderson; Pallavur V Sivakumar; Hong-Ping Ren; Fariba Barahmand-Pour; Don Foster; Chris Clegg; Wayne Kindsvogel; Rafael Ponce; Steven D Hughes; Kim Waggie Journal: PLoS One Date: 2013-06-25 Impact factor: 3.240